MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/infdis/jiu579

Медицинская библиотека · The Journal of infectious diseases · 2014

Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals.

Hodgson Susanne H, Ewer Katie J, Bliss Carly M, Edwards Nick J, Rampling Thomas, Anagnostou Nicholas A, de Barra Eoghan, Havelock Tom, Bowyer Georgina, Poulton Ian D, de Cassan Simone, Longley Rhea, Illingworth Joseph J, Douglas Alexander D, Mange Pooja B, Collins Katharine A, Roberts Rachel, Gerry Stephen, Berrie Eleanor, Moyle Sarah, Colloca Stefano, Cortese Riccardo, Sinden Robert E, Gilbert Sarah C, Bejon Philip, Lawrie Alison M, Nicosia Alfredo, Faust Saul N, Hill Adrian V S

Клиническое исследование I фазыКлиническое исследование II фазыСтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Circumsporozoite protein (CS) is the antigenic target for RTS,S, the most advanced malaria vaccine to date. Heterologous prime-boost with the viral vectors simian adenovirus 63 (ChAd63)-modified vaccinia virus Ankara (MVA) is the most potent inducer of T-cells in humans, demonstrating significant efficacy when expressing the preerythrocytic antigen insert multiple epitope-thrombospondin-related adhesion protein (ME-TRAP). We hypothesized that ChAd63-MVA containing CS may result in a significant clinical protective efficacy.

METHODS

We conducted an open-label, 2-site, partially randomized Plasmodium falciparum sporozoite controlled human malaria infection (CHMI) study to compare the clinical efficacy of ChAd63-MVA CS with ChAd63-MVA ME-TRAP.

RESULTS

One of 15 vaccinees (7%) receiving ChAd63-MVA CS and 2 of 15 (13%) receiving ChAd63-MVA ME-TRAP achieved sterile protection after CHMI. Three of 15 vaccinees (20%) receiving ChAd63-MVA CS and 5 of 15 (33%) receiving ChAd63-MVA ME-TRAP demonstrated a delay in time to treatment, compared with unvaccinated controls. In quantitative polymerase chain reaction analyses, ChAd63-MVA CS was estimated to reduce the liver parasite burden by 69%-79%, compared with 79%-84% for ChAd63-MVA ME-TRAP.

CONCLUSIONS

ChAd63-MVA CS does reduce the liver parasite burden, but ChAd63-MVA ME-TRAP remains the most promising antigenic insert for a vectored liver-stage vaccine. Detailed analyses of parasite kinetics may allow detection of smaller but biologically important differences in vaccine efficacy that can influence future vaccine development.

CLINICAL TRIALS REGISTRATION: NCT01623557.

Для цитирования: Hodgson Susanne H, Ewer Katie J, Bliss Carly M, Edwards Nick J, Rampling Thomas, Anagnostou Nicholas A, de Barra Eoghan, Havelock Tom, Bowyer Georgina, Poulton Ian D, de Cassan Simone, Longley Rhea, Illingworth Joseph J, Douglas Alexander D, Mange Pooja B, Collins Katharine A, Roberts Rachel, Gerry Stephen, Berrie Eleanor, Moyle Sarah, Colloca Stefano, Cortese Riccardo, Sinden Robert E, Gilbert Sarah C, Bejon Philip, Lawrie Alison M, Nicosia Alfredo, Faust Saul N, Hill Adrian V S. Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals.. The Journal of infectious diseases. 2014. DOI: 10.1093/infdis/jiu579.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.